Print Page   |   Contact Us   |   Sign In   |   Join iBIO
The Sunshine Act and Its Impact at Life Sciences Startups
Tell a Friend About This EventTell a Friend
The Sunshine Act and Its Impact at Life Sciences Startups

9/12/2014
When: Friday, September 12, 2014
11:30 a.m. - 1:30 p.m.
Where: hosted at McGuireWoods LLP
77 W. Wacker Dr.
Suite 4100
Chicago, Illinois  60601
United States
Contact: PROPEL Team
(312) 422-1111

« Go to Upcoming Event List  


In February 2013, CMS released the final rule implementing the Transparency Reports and Reporting of Physician Ownership or Investment Interests section of the Patient Protection and Affordable Care Act ("ACA"), commonly referred to as the "Sunshine Act." The Physician Payments Sunshine Act requires all U.S. drug and medical device manufacturers to report any gifts and payments made to physicians and teaching hospitals with a value totaling $100 annually or greater, as part of ACA. Failure to stay in compliance may result in fines ranging from $10,000 to $1,000,000 annually.

Join PROPEL for this opportunity to understand how the Sunshine Act and other recent healthcare policy changes impact life sciences startups. Whether your startup has a medical device, drug, diagnostics or another life sciences product, you are impacted by the ACA's Physician Payments Sunshine Act. We'll discuss what startups need to understand, when this impacts startups and how a startup can be compliant. We'll talk with experts in compliance and policy who will share their experiences in implementing these new policies.

Panelists will include:

  • Brian Beeler, Chief Compliance Officer & VP, Associate General Counsel, Horizon Pharma, Inc.
  • John Saran, Associate, McGuireWoods LLP

Registration is $15 through September 10, then it increases to $25. For questions, contact PROPEL@ibioinstitute.org or (312) 422-1111 ext. 6.


Association Management Software Powered by YourMembership.com®  ::  Legal